Last reviewed · How we verify
NCT06664840: MRD
MyRareDiet A Novel Diet Tracking Tool
NA trial testing MDR diet assessment in Urea Cycle Disorder in 60 participants. Not yet recruiting.
30 September 2025
Quick facts
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 60 |
| Start date | 15 November 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 31 December 2025 |
Drugs / interventions tested
- MDR diet assessment
- 24 hour recall
Conditions studied
- Urea Cycle Disorder — all drugs for Urea Cycle Disorder →
- Propionic Aciduria — all drugs for Propionic Aciduria →
- Maple Syrup Urine Disease — all drugs for Maple Syrup Urine Disease →
- Methylmalonic Acidemia — all drugs for Methylmalonic Acidemia →
Sponsor
Oregon Health and Science University
Who can join
Adults 1 to 80, any sex, with Urea Cycle Disorder or Propionic Aciduria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose to develop and validate MyRareDiet® (MRD) to address an unmet need in the inborn errors of metabolism (IEM) population to assist with dietary management designed to increase adherence and compliance to treatment guidelines, while facilitating the collection of dietary data from individuals with IEM for research purposes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06664840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urea Cycle Disorder
Currently open trials in the same condition.
- NCT04908319 — Hepatic Histopathology in Urea Cycle Disorders · recruiting
- NCT04612764 — Liver Disease in Urea Cycle Disorders · recruiting
Other Oregon Health and Science University trials
Trials by the same sponsor.
- NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
- NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
- NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
- NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
- NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06664840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
- Last refreshed: 30 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06664840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing